The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors.
Michael Anthony Carducci
Consultant or Advisory Role - Amgen
Montaser F. Shaheen
No relevant relationships to disclose
Channing Judith Paller
No relevant relationships to disclose
Julie E. Bauman
No relevant relationships to disclose
Nilofer Saba Azad
No relevant relationships to disclose
Poornima Shubhakar
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Rui Tang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Mark Stroh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Gregory R. Friberg
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Claire F. Verschraegen
No relevant relationships to disclose